CLAIMS

1. Composition of lipophilic molecules that can be diffused in aqueous medium, characterized in that it comprises at least one derivative of the aryl-carboxylic family and/or a lipophilic anti-inflammatory and/or a lipophilic anti-mycotic and/or a lipophilic analgesic of the morphine type and/or a lipophilic anti-allergic, in the form of salts of these molecules.

2. Composition of lipophilic molecules according to claim 1, wherein the molecule is a derivative of the aryl-carboxylic family combined with a substrate that makes possible a slow diffusion that is uniform and localized to the buccopharyngeal cavity.

3. Composition according to claim 1 or 2, wherein at least one derivative of the aryl-carboxylic family and/or the lipophilic anti-inflammatory and/or the lipophilic antimycotic and/or the lipophilic analgesic of the morphine type and/or the lipophilic anti-allergic is combined with at least one amino acid.

4. Composition according to claim 3, wherein the amino acid that is retained is lysine.

5. Composition according to one of claims 1, 2, 3 or 4, wherein it comprises a polymer agent that is selected from among the family of cellulose derivatives, more particularly carboxy-methyl cellulose that contains soda, hydroxy-ethyl cellulose, hydroxy-propyl cellulose, hydroxy-propyl methyl cellulose or promellose, or carboxy-methyl cellulose.

6. Composition according to any of claims 1 to 5, wherein it comprises a polymer agent that is selected from among the family of gums, such as guar gum, gum Arabic, or xanthane gum.

7. Composition for the treatment of buccopharyngeal ailments according to any of claims 1 to 6, wherein it comprises a polymer agent that is selected from among the compounds: alginic acid and derivatives, carboxy-vinyl polymer, carbomer, macrogols, polyethylene glycols, gelatin, povidone, or pectins.

8. Composition for the treatment of buccopharyngeal ailments according to any of claims 1 to 7, wherein it comprises a substrate that is selected from among the carbohydrates, more particularly lactose, glucose, saccharose, sorbitol, mannitol or xylitol.

9. Tablet including the composition according to any of claims 1 to 8, wherein it comprises the following formulation:

- ibuprofen lysinate: 25 mg
- magnesium stearate: 10 mg
- talc: 50 mg
- aspartame: 15 mg
- metolose: 70 mg
- Arome: 20 mg
- sorbitol: 810 mg

10. Tablet including the composition according to any of claims 1 to 8, wherein it comprises the following formulation:

- ketoprofen lysinate: 5 mg

- magnesium stearate: 10 mg
- talc: 50 mg
- aspartame: 15 mg
- metolose: 70 mg
- Arome: 20 mg
- sorbitol: 830 mg

11. Use of the composition according to any of claims 2 to 8 for the production of a medication designed to treat the buccopharyngeal ailments by diffusion.

12. Use of the tablet according to one of claims 9 or 10 for treating the buccopharyngeal ailments by diffusion.